EVAH Closes Series B Financing of $8.5 million

EVAH Corp. (EVAH or the company) has announced the successful completion of a Series B financing round, raising $8.5 million. This additional financing brings EVAH’s total funding since its launch in 2020 to $28.5 million.

A business and development platform in the animal health industry, EVAH specializes in the development of vaccines to prevent bacterial diseases in food animals. The company also designs microbiome solutions for improved growth performance and medicated feed against parasites.

NewsGuest UserMarch 29, 2023BIOOQuébecEVAH, animal health, vaccine production

The Government of Canada continues to invest in domestic vaccine production

The Government of Canada continues to make significant investments to strengthen Canada’s biomanufacturing and life sciences sector. Our approach prioritizes innovative solutions and long-term domestic biomanufacturing capacity right here at home. Since March 2020, over $1.8 billion has been invested across 34 projects to rebuild Canada’s vaccines, therapeutics and biomanufacturing capacity.

NewsGuest UserMarch 29, 2023BIOOQuébecvaccine production, biomanufacturing